Claudio Chini
Impact in
- Oncology top 5%
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 7
-
- Gastric Cancer Management and Outcomes 4
- Renal cell carcinoma treatment 1
- Advanced Breast Cancer Therapies 1
- Co-authors
- Ilaria Proserpio (6 shared papers)Graziella Pinotti (9 shared papers)Anastasios Stathis (3 shared papers)G. Pinotti (4 shared papers)Francesco Bertoni (2 shared papers)Franco Cavalli (3 shared papers)Emanuele Zucca (3 shared papers)Luca Mazzucchelli (1 shared paper)
- Journals
- Anti-Cancer Drugs (3 papers)La radiologia medica (3 papers)Annals of Oncology (3 papers)The Lancet Oncology (2 papers)Blood (1 paper)
- Partner nations
- ItalySwitzerlandAustralia
In The Last Decade
Claudio Chini
27 papers receiving 997 citations
Claudio Chini's Hit Papers
Peers
Comparison fields: 5 of 58
- Oncology 449
- Pathology and Forensic Medicine 151
- Infectious Diseases 154
- Cancer Research 96
- Hepatology 45
Countries citing papers authored by Claudio Chini
This map shows the geographic impact of Claudio Chini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Chini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Chini more than expected).
Fields of papers citing papers by Claudio Chini
This network shows the impact of papers produced by Claudio Chini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Chini. The network helps show where Claudio Chini may publish in the future.
Co-authors
The 25 scholars most cited alongside Claudio Chini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Hit paper breakdown → | 2020 | 488 |
| 2 | 2009 | 123 | |
| 3 | 2022 | 104 | |
| 4 | 2013 | 60 | |
| 5 | 2020 | 58 | |
| 6 | 2013 | 29 | |
| 7 | 2023 | 22 | |
| 8 | 2013 | 18 | |
| 9 | 2023 | 17 | |
| 10 | 2008 | 15 | |
| 11 | 2024 | 15 | |
| 12 | 2002 | 12 | |
| 13 | 2008 | 10 | |
| 14 | 2009 | 7 | |
| 15 | 2018 | 7 | |
| 16 | 2020 | 7 | |
| 17 | 2021 | 6 | |
| 18 | 2016 | 5 | |
| 19 | 2020 | 5 | |
| 20 | 2022 | 5 |
About Claudio Chini
Claudio Chini is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Oncology, Hepatology and Cancer Research, having authored 29 papers that have together received 1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Gastric Cancer Management and Outcomes (4 papers), Helicobacter pylori-related gastroenterology studies (3 papers), Pancreatic and Hepatic Oncology Research (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Breast Cancer Treatment Studies (2 papers), Renal cell carcinoma treatment (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Oncology (449 citations), Pathology and Forensic Medicine (151 citations), Infectious Diseases (154 citations), Cancer Research (96 citations) and Hepatology (45 citations). Claudio Chini has collaborated with scholars based in Italy, Switzerland and Australia. Frequent co-authors include Ilaria Proserpio, Graziella Pinotti, Anastasios Stathis, G. Pinotti, Francesco Bertoni, Franco Cavalli, Emanuele Zucca, Luca Mazzucchelli, C. Capella and E Pedrinis. Their work appears in journals such as Anti-Cancer Drugs, La radiologia medica, Annals of Oncology, The Lancet Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.